Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$538M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$379M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$337M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.14B |
| 2 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$466M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$420M |
| 4 |
Tesla
TSLA
|
+$251M |
| 5 |
IPHI
INPHI CORPORATION
IPHI
|
+$242M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.39% |
| 2 | Financials | 7.95% |
| 3 | Communication Services | 5.87% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Healthcare | 5.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PINC
3251
DELISTED
Premier
PINC
| $339K | ﹤0.01% |
9,754
-25,116
| -72% | -$867K |
|
3252
Sterling Infrastructure
STRL
$16.9B
| $339K | ﹤0.01% |
14,038
-26,985
| -66% | -$604K |
|
3253
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.93B
| $339K | ﹤0.01% |
2,500
-220,000
| -99% | -$28.9M |
|
3254
Amerant Bancorp
AMTB
$1.17B
| $338K | ﹤0.01% |
15,824
-3,134
| -17% | -$65.7K |
|
3255
Liberty Latin America Class C
LILAK
$1.67B
| $338K | ﹤0.01% |
26,467
-130,680
| -83% | -$1.68M |
|
3256
World Acceptance Corp
WRLD
$902M
| $337K | ﹤0.01% |
2,110
-4,063
| -66% | -$595K |
|
|
TECX
3257
Tectonic Therapeutic
TECX
$552M
| $337K | ﹤0.01% |
3,158
-2,391
| -43% | -$283K |
|
|
CNSL
3258
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $336K | ﹤0.01% |
38,329
-52,521
| -58% | -$422K |
|
3259
VanEck Pharmaceutical ETF
PPH
$912M
| $335K | ﹤0.01% |
4,596
+4,496
| +4,496% | +$321K |
|
3260
HCI Group
HCI
$2.29B
| $334K | ﹤0.01% |
3,361
-4,424
| -57% | -$359K |
|
|
CMO
3261
DELISTED
Capstead Mortgage Corp.
CMO
| $334K | ﹤0.01% |
54,307
-75,945
| -58% | -$490K |
|
3262
Huron Consulting
HURN
$2.41B
| $333K | ﹤0.01% |
6,786
-17,880
| -72% | -$961K |
|
3263
Protagonist Therapeutics
PTGX
$8.83B
| $333K | ﹤0.01% |
7,405
-30,461
| -80% | -$1.01M |
|
|
SAL
3264
DELISTED
Salisbury Bancorp, Inc.
SAL
| $333K | ﹤0.01% |
13,084
-3,658
| -22% | -$84.1K |
|
3265
Zymeworks
ZYME
$1.66B
| $332K | ﹤0.01% |
9,558
-7,467
| -44% | -$237K |
|
|
FRBK
3266
DELISTED
Republic First Bancorp Inc
FRBK
| $332K | ﹤0.01% |
83,298
-32,140
| -28% | -$129K |
|
3267
UNIFI
UFI
$128M
| $331K | ﹤0.01% |
13,597
-4,040
| -23% | -$108K |
|
3268
Ranpak Holdings
PACK
$486M
| $330K | ﹤0.01% |
13,200
-18,988
| -59% | -$399K |
|
3269
PUT
Honeywell
HON
$79.1B
| $329K | ﹤0.01% |
1,592
| – | – |
|
3270
Hercules Capital
HTGC
$3.16B
| $329K | ﹤0.01% |
19,300
-1,757
| -8% | -$30.1K |
|
3271
BlackRock Floating Rate Income Trust
BGT
$324M
| $326K | ﹤0.01% |
+23,976
| New | +$303K |
|
3272
PUT
Vanguard Real Estate ETF
VNQ
$39.2B
| $326K | ﹤0.01% |
3,200
| – | – |
|
3273
American Coastal Insurance
ACIC
$536M
| $325K | ﹤0.01% |
57,145
-14,730
| -20% | -$90.1K |
|
3274
Aldeyra Therapeutics
ALDX
$92.9M
| $325K | ﹤0.01% |
28,695
-22,050
| -43% | -$265K |
|
|
REVG
3275
DELISTED
REV Group
REVG
| $324K | ﹤0.01% |
20,673
-20,386
| -50% | -$369K |
|
Similar funds
Barclays's Q2 2021 Portfolio in Review
As of Q2 2021, Barclays held 5,234 positions worth $212B, up 14% from $186B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Barclays deployed $11.1B of net new capital in Q2 2021, opening 558 new positions and adding to 1,559 existing holdings. Its largest new stake was Proofpoint, Inc.: 1,241,690 shares worth $216M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 13% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.14B trimmed.
- Barclays's largest Q2 2021 buy was Proofpoint, Inc.: 1,241,690 shares worth $216M.
- Barclays added most to iShares US Real Estate ETF in Q2 2021, an estimated $1.48B increase.
- Barclays's biggest Q2 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.14B.
- Barclays fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $466M.
- Barclays's ten largest holdings make up 36% of its $212B portfolio in Q2 2021.
- Barclays opened 558 new positions and closed 327 in Q2 2021.
- Barclays's portfolio value rose 14% quarter-over-quarter to $212B.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.